BIOMAT Database Logo BIOMAT Database Logo

Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients. 1998

G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Bahrain.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue

Related Publications

G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
November 1999, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
October 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients.
September 2004, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients.
November 2000, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
September 2004, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
November 1997, Transplantation,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile.
April 2008, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Individualization of mycophenolate mofetil dose in renal transplant recipients.
March 2006, Expert opinion on pharmacotherapy,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients.
January 1999, Transplantation proceedings,
G M Abouna, and A S al Arrayed, and E Farid, and C K Awad, and S A Sharqawi, and M Tantawi
Withdrawal of mycophenolate mofetil in stable renal transplant recipients.
April 2000, Transplantation,
Copied contents to your clipboard!